| Vidya Rajaram Devarajan, MD | |
|
1 Medical Village Dr, Edgewood, KY 41017-3403 | |
| (859) 757-4446 | |
| (859) 344-1999 |
| Full Name | Vidya Rajaram Devarajan |
|---|---|
| Gender | Female |
| Speciality | Infectious Disease |
| Experience | 34 Years |
| Location | 1 Medical Village Dr, Edgewood, Kentucky |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063658623 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 92500 (Ohio) | Secondary |
| 207RI0200X | Internal Medicine - Infectious Disease | 44007 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Elizabeth Edgewood | Edgewood, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Summit Medical Group, Inc | 2163326240 | 693 |
News Archive
Chai-Na-Ta Corp. (the "Company"), announced that the Board of Directors of the Company has approved the extension of a non-revolving term loan facility ("Loan") of HK$ 54.7 million (approximately CAD$7.7 million) offered by More Growth Finance Limited ("More Growth"), a company formally under common control.
Ambit Biosciences Corporation announced today the enrollment and dosing at the University of Texas M. D. Anderson Cancer Center of the first patient in the ACE (AC220 Monotherapy Efficacy) Phase 2 pivotal trial in patients with relapsed or refractory acute myeloid leukemia (AML).
During a stop in Denver Monday, House Speaker Nancy Pelosi said President Barack Obama plans to propose a "health care bill that will be 'much smaller' than the House bill but 'big enough' to put the country on a 'path' toward health care reform" within days, FoxNews.com reports. According to a senior administration official, Obama plans to unveil his proposal Wednesday
Inland Empire residents suffering from knee pain can finally take a sigh of relief thanks to the availability of minimally traumatic, patient-specific knee resurfacing implants.
Celsion Corporation, a leading oncology drug development company, today announced financial results for the fourth quarter and year ended December 31, 2009. Management also highlighted the progress made in clinical trials of ThermoDox®, Celsion's heat activated liposomal encapsulation of doxorubicin, including the Company's pivotal Phase III trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer, and recurrent chest wall breast cancer.
› Verified 5 days ago
| Entity Name | Summit Medical Group, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881026169 PECOS PAC ID: 2163326240 Enrollment ID: O20031120000738 |
News Archive
Chai-Na-Ta Corp. (the "Company"), announced that the Board of Directors of the Company has approved the extension of a non-revolving term loan facility ("Loan") of HK$ 54.7 million (approximately CAD$7.7 million) offered by More Growth Finance Limited ("More Growth"), a company formally under common control.
Ambit Biosciences Corporation announced today the enrollment and dosing at the University of Texas M. D. Anderson Cancer Center of the first patient in the ACE (AC220 Monotherapy Efficacy) Phase 2 pivotal trial in patients with relapsed or refractory acute myeloid leukemia (AML).
During a stop in Denver Monday, House Speaker Nancy Pelosi said President Barack Obama plans to propose a "health care bill that will be 'much smaller' than the House bill but 'big enough' to put the country on a 'path' toward health care reform" within days, FoxNews.com reports. According to a senior administration official, Obama plans to unveil his proposal Wednesday
Inland Empire residents suffering from knee pain can finally take a sigh of relief thanks to the availability of minimally traumatic, patient-specific knee resurfacing implants.
Celsion Corporation, a leading oncology drug development company, today announced financial results for the fourth quarter and year ended December 31, 2009. Management also highlighted the progress made in clinical trials of ThermoDox®, Celsion's heat activated liposomal encapsulation of doxorubicin, including the Company's pivotal Phase III trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer, and recurrent chest wall breast cancer.
› Verified 5 days ago
| Entity Name | Infectious Disease Consultants Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033154919 PECOS PAC ID: 0749243806 Enrollment ID: O20041109000989 |
News Archive
Chai-Na-Ta Corp. (the "Company"), announced that the Board of Directors of the Company has approved the extension of a non-revolving term loan facility ("Loan") of HK$ 54.7 million (approximately CAD$7.7 million) offered by More Growth Finance Limited ("More Growth"), a company formally under common control.
Ambit Biosciences Corporation announced today the enrollment and dosing at the University of Texas M. D. Anderson Cancer Center of the first patient in the ACE (AC220 Monotherapy Efficacy) Phase 2 pivotal trial in patients with relapsed or refractory acute myeloid leukemia (AML).
During a stop in Denver Monday, House Speaker Nancy Pelosi said President Barack Obama plans to propose a "health care bill that will be 'much smaller' than the House bill but 'big enough' to put the country on a 'path' toward health care reform" within days, FoxNews.com reports. According to a senior administration official, Obama plans to unveil his proposal Wednesday
Inland Empire residents suffering from knee pain can finally take a sigh of relief thanks to the availability of minimally traumatic, patient-specific knee resurfacing implants.
Celsion Corporation, a leading oncology drug development company, today announced financial results for the fourth quarter and year ended December 31, 2009. Management also highlighted the progress made in clinical trials of ThermoDox®, Celsion's heat activated liposomal encapsulation of doxorubicin, including the Company's pivotal Phase III trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer, and recurrent chest wall breast cancer.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Vidya Rajaram Devarajan, MD Po Box 635283, Cincinnati, OH 45263-5283 Ph: (859) 757-4446 | Vidya Rajaram Devarajan, MD 1 Medical Village Dr, Edgewood, KY 41017-3403 Ph: (859) 757-4446 |
News Archive
Chai-Na-Ta Corp. (the "Company"), announced that the Board of Directors of the Company has approved the extension of a non-revolving term loan facility ("Loan") of HK$ 54.7 million (approximately CAD$7.7 million) offered by More Growth Finance Limited ("More Growth"), a company formally under common control.
Ambit Biosciences Corporation announced today the enrollment and dosing at the University of Texas M. D. Anderson Cancer Center of the first patient in the ACE (AC220 Monotherapy Efficacy) Phase 2 pivotal trial in patients with relapsed or refractory acute myeloid leukemia (AML).
During a stop in Denver Monday, House Speaker Nancy Pelosi said President Barack Obama plans to propose a "health care bill that will be 'much smaller' than the House bill but 'big enough' to put the country on a 'path' toward health care reform" within days, FoxNews.com reports. According to a senior administration official, Obama plans to unveil his proposal Wednesday
Inland Empire residents suffering from knee pain can finally take a sigh of relief thanks to the availability of minimally traumatic, patient-specific knee resurfacing implants.
Celsion Corporation, a leading oncology drug development company, today announced financial results for the fourth quarter and year ended December 31, 2009. Management also highlighted the progress made in clinical trials of ThermoDox®, Celsion's heat activated liposomal encapsulation of doxorubicin, including the Company's pivotal Phase III trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer, and recurrent chest wall breast cancer.
› Verified 5 days ago
Alice Hall, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Village Dr, Edgewood, KY 41017 Phone: 859-301-8074 Fax: 859-301-4945 | |
Colleen M Darnell, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Village Dr, Edgewood, KY 41017 Phone: 859-301-4000 Fax: 859-301-4001 | |
Charles M Bernstein, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Village Dr, St. Elizabeth Healthcare, Edgewood, KY 41017 Phone: 859-301-2423 Fax: 859-301-2066 | |
Dr. Minsig Choi, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Village Dr, Edgewood, KY 41017 Phone: 859-301-4000 Fax: 859-301-4001 | |
Robert J Wagner, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Village Dr, Edgewood, KY 41017 Phone: 859-301-8074 Fax: 859-301-4945 | |
Ryan Daniel Weprin, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Village Dr, Edgewood, KY 41017 Phone: 859-301-8074 Fax: 859-301-4945 |